Loading…
Lobbying Income
$532K
Filings
132
Unique Clients
3
Active Period
2009–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
American Middle Class Tax (AMT) Relief Act of 2007
2010 · first_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
Follow on Biologics provisions in HR3590, HR1427, and HR1548, also Health Care and Education Reconcilation Act of 2010
Client expense: — · Firm income: $10,000
Matched citations: HR3590
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
Follow on Biologics provisions in HR3590, HR1427, and HR1548, also Health Care and Education Reconcilation Act of 2010
Client expense: — · Firm income: $10,000
Matched citations: HR1427
Pathway for Biosimilars Act
2010 · first_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
Follow on Biologics provisions in HR3590, HR1427, and HR1548, also Health Care and Education Reconcilation Act of 2010
Client expense: — · Firm income: $10,000
Matched citations: HR1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
America's Healthy Future Act of 2009- issues related to importation of pharmaceutical products from foreign countries. -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics; -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · fourth_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
America's Healthy Future Act of 2009- issues related to importation of pharmaceutical products from foreign countries. -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics; -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
America's Healthy Future Act of 2009- issues related to importation of pharmaceutical products from foreign countries. -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics; -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
Client expense: — · Firm income: $20,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · second_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
H.R. 1427- Promoting Innovation and Access to Life-Saving Medicine Act : regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics (continued on separate page) H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · second_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
H.R. 1427- Promoting Innovation and Access to Life-Saving Medicine Act : regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics (continued on separate page) H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · second_quarter · Client: PHRMA(ON BEHALF OF WE WORK FOR HEALTH)
H.R. 1427- Promoting Innovation and Access to Life-Saving Medicine Act : regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics (continued on separate page) H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $20,000
Matched citations: S. 726
Source: Senate LDA